Get the Stockscreener App
13.76
0.00%
0.00
Organon Co stock is traded at $13.76, with a volume of 2.65M.
It is up +0.00% in the last 24 hours and up +0.66% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$13.76
Open:
$13.77
24h Volume:
2.65M
Relative Volume:
1.17
Market Cap:
$3.61B
Revenue:
$6.16B
Net Income/Loss:
$246.00M
P/E Ratio:
14.66
EPS:
0.9387
Net Cash Flow:
$708.00M
1W Performance:
-0.36%
1M Performance:
+0.66%
6M Performance:
+47.48%
1Y Performance:
+46.70%
1-Day Range:
$13.74
$13.78
1-Week Range:
$13.74
$13.80
52-Week Range:
$5.69
$13.83
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.76 | 3.61B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,257.03 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.56 | 615.87B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.42 | 504.37B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.95 | 360.08B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.62 | 286.29B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-26 | Upgrade | Piper Sandler | Underweight → Neutral |
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Zacks Investment Research
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
USU6836GAB42 Bond Yield and Price — BONDSCOM:USU6836GAB42 - TradingView
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Organon & Co stock hits 52-week high at 13.79 USD - Investing.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon presents VTAMA analysis: Organon stock gains 1.16 percent - AD HOC NEWS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Tangible book value per share of Organon & Co. – HAN:7XP - TradingView
Organon & Co. Revenue Breakdown – HAN:7XP - TradingView
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - ETPharma.com
Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan - Firstpost
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - Dealroom
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review - Yahoo Finance
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN) - Seeking Alpha
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - pharma.economictimes.indiatimes.com
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Canada
Organon & Co stock hits 52-week high at $13.78 - Investing.com India
Organon & Co stock hits 52-week high at $13.78 - investing.com
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com UK
Henlius - henlius.com
Organon earnings up next: Can drugmaker rebound after Q1 miss? - investing.com
Organon (OGN) Move: Ends Up by 0.07% at $13.74 on the Day; Technical Setup: the $13.05 to $14.43 Range Remains in FocusBox Spread - Vinanet
Sun Pharma completes $11.75bn financing syndication for Organon acquisition - Generics and Biosimilars Initiative
Organon (OGN) Trading: Ends Up by 0.37% at $13.73 at the Close; Next Session: the Supplied Trading Band Runs From $13.04 to $14.42 under the Current SnapshotOvernight Profile - Vinanet
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organon Co Stock (OGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Head of Mfg & Supply |
Aug 05 '26 |
Sale |
13.57 |
14,761 |
200,307 |
18,475 |
| JULIANA P DRINANE | Officer |
Aug 05 '26 |
Proposed Sale |
13.57 |
14,761 |
200,307 |
0 |
| Holzbaur Lynette | SVP and Corporate Controller |
May 06 '26 |
Buy |
13.35 |
26,448 |
353,080 |
52,851 |
| Holzbaur Lynette | Affiliate |
May 06 '26 |
Proposed Sale |
13.35 |
26,448 |
353,080 |
0 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '26 |
Option Exercise |
0.00 |
17,925 |
0 |
105,265 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '26 |
Option Exercise |
0.00 |
18,513 |
0 |
96,147 |
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
73,494 |
| Holzbaur Lynette | SVP and Corporate Controller |
Mar 31 '26 |
Option Exercise |
0.00 |
10,967 |
0 |
28,316 |
| Morrissey Joseph T. Jr. | Interim CEO |
Mar 31 '26 |
Option Exercise |
0.00 |
24,584 |
0 |
127,907 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '26 |
Option Exercise |
0.00 |
13,431 |
0 |
34,867 |
1.33%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):